Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans.
about
Deciphering the genetic basis for polyketide variation among mycobacteria producing mycolactonesMycobacterium ulcerans cytotoxicity in an adipose cell modelA newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxinA Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cellsGlobally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone FBacterial Toxins as Pathogen Weapons Against PhagocytesDevelopment of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycinBactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans diseaseAntioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicityAnalysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone.Emergence of a unique group of necrotizing mycobacterial diseases.Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulceransProteomic analysis of the action of the Mycobacterium ulcerans toxin mycolactone: targeting host cells cytoskeleton and collagen.Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice.Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in micePhotodegradation of the Mycobacterium ulcerans toxin, mycolactones: considerations for handling and storageHistopathologic features of Mycobacterium ulcerans infection.Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence.Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response.Findings from a buruli ulcer mouse model studyTreating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?Development and application of real-time PCR assay for quantification of Mycobacterium ulcerans DNA.Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infectionDynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humansMycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria.Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice.Structural and functional cellular changes induced by Burkholderia pseudomallei rhamnolipid.The chemistry and biology of mycolactones.Conditioned medium from enterohemorrhagic Escherichia coli-infected T84 cells inhibits signal transducer and activator of transcription 1 activation by gamma interferon.Naturally occurring a loss of a giant plasmid from Mycobacterium ulcerans subsp. shinshuense makes it non-pathogenic.
P2860
Q21263166-11044758-B736-4AE7-AE6E-EBE8707A3917Q24514493-0FDD5C6D-3B71-4CAF-8C00-12CF396376B6Q24524154-BE6ADE7E-4024-4B3C-ABA9-89A3D79F2EA0Q24548793-2E595F72-4C6A-42A9-8544-8A250A2A64B6Q24673638-742A3643-9817-4850-811B-B0397007A004Q26766446-C89DB090-F4CE-46B6-A66F-8B31100D1135Q28469338-5C70B9C9-2265-4776-8952-E7A4E324D50FQ28487137-D64AEBDF-54D4-4E8C-860F-4BF59809EBD7Q28748563-481D93C2-82D7-4300-9FE8-52485B3889A3Q33196152-3B205613-26F2-4A29-A663-959C339D3098Q33643091-4B208C62-5E95-46F0-A14A-45ADA3B89A5FQ33714520-2F2E7EA6-A51B-4CC7-9461-79C1806EAF32Q34016179-2875063D-349C-4CD5-8E6E-C3BE5F54BC8CQ34033119-004C8D47-599E-49BE-999D-BD98CC49EAC5Q34144367-DC0FE370-0D33-4A75-98A3-71AC9A0F1643Q34238411-7A723234-D4BD-41C5-942C-C55C43EEE2EBQ34396322-4BE5DC6A-CC7C-475B-9411-CBFFF20469EAQ34581754-9715471C-5AAD-49FA-B81A-86AC9450C6EEQ34602038-3D08AAD4-FC81-45FF-9AA4-CAC80D5D9509Q35623100-F271040A-7692-4698-A01C-8798BCA64645Q35625819-2243FA7B-1191-4CE3-95DA-573A5842A1B1Q35922743-69C70846-2805-4073-9A7A-F37E21C4F9A7Q35949741-5F4A2E6C-2425-4A7B-9AA9-B2DD051E1FB6Q37051036-6D559B39-A277-45E5-AD63-BB02C10DD045Q37170768-7207C415-3C48-472F-80C1-5CA07ED6CABFQ39743356-EE596F6D-F870-42AB-8DF4-12F88FE9E263Q39746007-00D64281-FD20-4ADF-9270-63C0B15CD894Q41469222-4D89C3EB-346C-417A-A63F-E501CD50FC2FQ43254870-681DB7A8-F01E-40E7-A0F6-B481B2F4C9FAQ55247742-36046504-D872-4143-A4A0-D74B05F39FAA
P2860
Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans.
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Partial purification and chara ...... ced by Mycobacterium ulcerans.
@ast
Partial purification and chara ...... ced by Mycobacterium ulcerans.
@en
type
label
Partial purification and chara ...... ced by Mycobacterium ulcerans.
@ast
Partial purification and chara ...... ced by Mycobacterium ulcerans.
@en
prefLabel
Partial purification and chara ...... ced by Mycobacterium ulcerans.
@ast
Partial purification and chara ...... ced by Mycobacterium ulcerans.
@en
P2093
P2860
P1476
Partial purification and chara ...... ced by Mycobacterium ulcerans.
@en
P2093
P2860
P304
P407
P577
1998-02-01T00:00:00Z